These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21962172)

  • 1. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
    Vemuri N; Michelis MF; Matalon A
    BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M;
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ; Laville M;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
    Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
    Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
    Wilson RJ; Keith MS; Preston P; Copley JB
    Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
    Finn WF; Joy MS; Hladik G;
    Clin Nephrol; 2004 Sep; 62(3):193-201. PubMed ID: 15481851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
    Hutchison AJ; Barnett ME; Krause R; Kwan JT; Siami GA;
    Nephron Clin Pract; 2008; 110(1):c15-23. PubMed ID: 18667837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
    Keith MS; Wilson RJ; Preston P; Copley JB
    Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
    Ohno M; Ohashi H; Oda H; Yokoyama H; Okada M; Nagaya M; Izumi K; Ito H; Katoh S
    Perit Dial Int; 2013; 33(3):297-303. PubMed ID: 23209037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
    Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.